Sofia Sterner Isaksson, Henrik Imberg, Irl B Hirsch, Erik Schwarcz, Jarl Hellman, Magnus Wijkman, Jan Bolinder, Thomas Nyström, Helene Holmer, Sara Hallström, Arndís F Ólafsdóttir, Sofia Pekkari, William Polonsky, Marcus Lind
Discordance between mean glucose and time in range in relation to HbA1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials
Diabetologia
galicia spain one first regions worldwide incorporate nirsevimab universal respiratory syncytial virus rsv prophylaxis infants immunisation programme nirsegal longitudinal populationbased study aimed assess nirsevimab effectiveness preventing hospitalisations ie admittance hospital 202324 immunisation campaign nirsevimab galicia began sept 25 2023 concluded march 31 2024 campaign targeted three groups infants born campaign seasonal group infants younger 6 months start campaign catchup group infants aged 624 months highrisk factors start campaign highrisk group infants seasonal group offered immunisation first day life discharge hospital infants catchup highrisk groups received electronic appointments attend public hospital healthcare centre nirsevimab administration interim analysis used data collected sept 25 dec 31 2023 children born dec 15 2023 data retrieved public health registries nirsevimab effectiveness preventing rsvassociated lower respiratory tract infection lrti hospitalisations severe rsvrelated lrti requiring intensive care unit admission mechanical ventilation oxygen support allcause lrti hospitalisations allcause hospitalisations estimated using adjusted poisson regression models data five past rsv seasons 201617 201718 201819 201920 202223 excluding covid19 pandemic period used estimate number rsvrelated lrti hospitalisations averted along iqr number needed immunise avoid one case 202324 season estimated averted cases nirsevimab safety routinely monitored nirsegal study protocol registered clinicaltrialsgov nct06180993 followup participants ongoing 9408 917 10 259 eligible infants seasonal catchup groups received nirsevimab including 6220 899 6919 seasonal group 3188 954 3340 catchup group 360 highrisk group offered nirsevimab 348 97 received infants seasonal catchup groups included analyses estimate nirsevimab effectiveness impact events highrisk group catchup seasonal groups combined 30 03 9408 infants received nirsevimab 16 19 851 receive nirsevimab hospitalised rsvrelated lrti corresponding effectiveness 820 95 ci 656902 effectiveness 869 691942 severe rsvrelated lrti requiring oxygen support 692 559780 allcause lrti hospitalisations 662 560737 allcause hospitalisations nirsevimab effectiveness endpoints severe rsvrelated lrti could estimated events rsvrelated lrti hospitalisations reduced 898 iqr 875903 number needed immunise avoid one rsvrelated lrti hospitalisation 25 iqr 2432 severe adverse events related nirsevimab registered nirsevimab substantially reduced infant hospitalisations rsvassociated lrti severe rsvassociated lrti requiring oxygen allcause lrti given realworld conditions findings offer policy makers health authorities robust realworld populationbased evidence guide development strategies rsv prevention sanofi astrazeneca spanish translation abstract see supplementary materials section